Recent Quotes (30 days)

You have no recent quotes
chg | %

Microbix Biosystems Inc  

(Public, TSE:MBX)   Watch this stock  
Find more results for MBX
0.265
-0.015 (-5.36%)
Feb 12 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.26 - 0.28
52 week 0.20 - 0.66
Open 0.28
Vol / Avg. 25,390.00/73,464.00
Mkt cap 23.69M
P/E 33.54
Div/yield     -
EPS 0.01
Shares 84.70M
Beta -0.89
Inst. own     -
Feb 12, 2016
Q1 2016 Microbix Biosystems Inc Earnings Release (Estimated)
Dec 31, 2015
Q4 2015 Microbix Biosystems Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 19.07% 6.92%
Operating margin 1.15% 3.93%
EBITD margin - 15.77%
Return on average assets 7.06% 2.96%
Return on average equity 12.07% 5.22%
Employees 20 -
CDP Score - -

Address

265 Watline Ave
MISSISSAUGA, ON L4Z 1P3
Canada
+1-905-3618910 (Phone)
+1-905-3618911 (Fax)

Website links

Description

Microbix Biosystems Inc is a Canada-based Company engaged in developing biological products and technologies. The Company developed a pipeline of selected biological technologies including Virusmax (Influenza Virus Yield Enhancement Technology), LumiSort (Semen Sexing Technology) and the thrombolytic drug, Kinlytic (Urokinase). The Company specializes in developing biological technologies, which leads to the development of a pipeline of products in three areas biotherapeutics, vaccines and non-therapeutic biologics. The Company’s product categories include Infectious Disease Antigens, Proficiency Testing and Adenovirus Vectors. The Virology business develops, manufactures and distributes infectious disease antigens for the medical diagnostic and vaccine research industries. The Company has commercialized approximately 60 products derived from infectious pathogens cultured and processed at its facilities.

Officers and directors

William J. Gastle Executive Chairman of the Board
Vaughn C. Embro-Pantalony President, Chief Executive Officer, Director
Charles S. Wallace Chief Financial Officer
Peter M. Blecher Independent Director
Mark A. Cochran Independent Director
Cameron L Groome Independent Director
Martin A. Marino Independent Director
Andrew Christopher Pollock Independent Director